Abstract
Terbinafine is a highly potent drug against dermatophytes. Data regarding its effectiveness against Candida species are few and variable. Our purpose was to evaluate the efficacy and safety of oral terbinafine in patients with Candida nail infection. In an open-label uncontrolled study, 20 patients completed 16 weeks of treatment with terbinafine, 250 mg/day, and an additional 8 weeks with placebo. Efficacy was assessed clinically and mycologically at weeks 0 (baseline), 4, 8, 16, 24, 36, and 48. Routine laboratory studies were performed at baseline and weeks 4, 8, and 16. At the end of the trial 60% of target nails were cured clinically and mycologically; in 10% there was mycologic cure with residual clinical signs, in 25% a moderate improvement (> 50%), and failure in only 5% (one patient). Most nails were infected by Candida parapsilosis. Two of 28 patients showed mild reversible elevation of liver enzymes 1 month after initiation of terbinafine treatment. The administration of terbinafine for 16 weeks is effective in the treatment of Candida nail infection. Liver enzyme values should be determined during the first month of treatment.
References
Sep 1, 1992·Clinical and Experimental Dermatology·Y M Clayton
Feb 1, 1992·The British Journal of Dermatology·A Y Finlay
Mar 1, 1989·Clinical and Experimental Dermatology·Y M Clayton
Apr 1, 1985·Sabouraudia·S ShadomyR J Gebhart
Jan 1, 1988·The British Journal of Dermatology·R J HayJ D Wilkinson
Mar 1, 1994·Clinical and Experimental Dermatology·J FaergemannL Millerioux
Apr 1, 1994·The British Journal of Dermatology·S NoltingG Weidinger
Citations
Dec 18, 2003·Clinics in Dermatology·Aditya K GuptaElizabeth A Cooper
Dec 20, 2002·Clinics in Dermatology·Joseph Obadiah, Richard Scher
Jul 1, 1998·International Journal of Dermatology·B Amichai, M H Grunwald
Oct 9, 1999·International Journal of Dermatology·J E ArreseG E Piérard
Oct 9, 1999·International Journal of Dermatology·A K Gupta, J Lambert
Dec 6, 2000·Mycoses·R SegalZ Segal
Feb 24, 2001·Mycoses·P GautretJ L Jacquemin
Dec 17, 2002·Journal of the European Academy of Dermatology and Venereology : JEADV·A K GuptaR Summerbell
Jul 22, 2005·International Journal of Clinical Practice·S H Wang, C C Chi
Aug 12, 2000·Drugs & Aging·A K Gupta
Jul 28, 2001·Clinical Pharmacokinetics·D Debruyne, A Coquerel
Nov 30, 2000·Current Infectious Disease Reports· Del Rosso JQ
Jan 26, 2007·Advances in Dermatology·Daniel S Loo
Sep 2, 2005·International Journal of Dermatology·Erin M WarshawDebra D Fett
Apr 4, 2007·Dermatologic Therapy·Justin J Finch, Erin M Warshaw
May 1, 2012·Mycoses·Chander Grover, Ananta Khurana
Jun 15, 2011·Mycoses·Lauren Van Duyn Graham, Boni E Elewski
Nov 21, 2014·The British Journal of Dermatology·M AmeenM Richardson
Sep 4, 2007·The American Journal of Medicine·Chia-Hsuin ChangArnold K Chan
Sep 6, 2003·Dermatologic Clinics·Aditya K Gupta, Jennifer E Ryder
Mar 20, 2004·The British Journal of Dermatology·B J Cribier, R Bakshi
May 22, 2003·Dermatologic Clinics·Aditya K GuptaRichard C Summerbell
Aug 19, 2005·Expert Review of Anti-infective Therapy·Adolfo C Fernandez-ObregonCarolyn Willis
Jan 13, 2001·Dermatologic Clinics·M MoossaviR K Scher
Dec 10, 2016·Pharmaceutical Biology·Renata Cougo MoraesGeorge González Ortega
Jan 27, 2000·Drug Safety : an International Journal of Medical Toxicology and Drug Experience·A K Gupta, N H Shear
May 17, 2002·Journal of the American Podiatric Medical Association·Aditya K Gupta
Jun 7, 2007·Mycopathologia·Valda Teixeira FigueiredoJúnia Soares Hamdan
May 20, 2008·The Journal of Dermatological Treatment·Robert BaranJavier I Garduno
Dec 13, 2002·American Journal of Clinical Dermatology·Malcolm J M DarkesKaren L Goa
May 21, 1998·Antimicrobial Agents and Chemotherapy·N S RyderI Leitner
Mar 4, 2021·Mycoses·Michelle J ChangShari R Lipner